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Abstract Mitochondrial DNA (mtDNA) diseases are a
group of neuromuscular diseases that often cause suffering
and premature death. New mitochondrial replacement tech-
niques (MRTs) may offer women with mtDNA diseases the
opportunity to have healthy offspring to whom they are
genetically related. MRTs will likely be ready to license for
clinical use in the near future and a discussion of the ethics of
the clinical introduction ofMRTs is needed. This paper begins
by evaluating three concerns about the safety of MRTs for
clinical use on humans: (1) Is it ethical to use MRTs if safe
alternatives exist? (2) Would persons with three genetic
contributors be at risk of suffering? and (3) Can society trust
that MRTs will be made available for humans only once
adequate safety testing has taken place, and that MRTs will
only be licensed for clinical use in a way thatminimises risks?
It is then argued that the ethics debate about MRTs should be
reoriented towards recommendingways to reduce the possible
risks of MRT use on humans. Two recommendations are
made: (1) licensed clinical access to MRTs should only be
granted to prospective parents if they intend to tell their
children about their MRT conception by adulthood; and (2)
sex selection should be used in conjunction with the clinical
use ofMRTs, in order to reduce transgenerational health risks.
Keywords Donation  Embryo  Genetics  IVF 
Three-parent
It is estimated that about 1 in every 6500 children in the
UK is affected by a mitochondrial DNA (mtDNA) disease,
which makes this group of neuromuscular diseases one of
the most prevalent (Schaefer et al. 2008; DH 2014a). These
diseases often result in considerable suffering and even
death. However, the development of new mitochondrial
replacement techniques (MRTs) could allow parents to
conceive children to whom they are genetically related and
who will not suffer from these diseases. The two most
promising MRTs in development are maternal spindle
transfer (MST) and pronuclear transfer (PNT), and no
children have been born with either of these techniques to
date.
Following consultations by the Nuffield Council on
Bioethics (NCB) (2012), the UK Human Fertilisation and
Embryology Authority (HFEA) (2013a) and the UK
Department of Health (2014a, b), the UK parliament voted
in early 2015 to approve regulations that permit the
licensed clinical use of MST and PNT (HFEA 2015). These
new MRT regulations entitled The Human Fertilisation
and Embryology (Mitochondrial Donation) Regulations
2015 (HFE Regulations 2015), come into force on 29
October 2015 and make amendments to the Human Fer-
tilisation and Embryology Act 1990 (HFE Act 1990) (as
amended). However, before MRTs can transition from lab
to clinic in the UK, the HFEA must first develop a
licensing framework to evaluate applications from clini-
cians wishing to use these techniques, on a case by case
basis (HFEA 2015). This framework must be able to
account for the many ethical and scientific challenges that
accompany the use of these techniques and according to the
HFEA must ‘ensure that any children born have the best
chance of a healthy life’ (HFEA 2015). Policymakers and
research institutes from the UK, Sweden, and the USA,
among others, have recommended that careful ethical
consideration should be given when determining the con-
ditions under which MRTs should first be made available
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in clinics, in order to minimise human exposure to risks
wherever possible (NCB 2012: pp. 1–14; SNCME 2013;
FDA 2014a, b, c).
A small but valuable body of literature discussing the
ethics of using MRTs on humans currently exists. How-
ever, despite the UK Parliament’s recent approval of the
HFE Regulations 2015, new research on this area of ethical
debate remains scarce. This paper makes an important
contribution to the existing literature by providing an up-
to-date and critical discussion of several of the key ethical
concerns (especially the safety and risks) surrounding the
clinical introduction of MRTs. In response to the HFEA’s
movement toward licensing MRT’s for clinical use, this
paper also recommends ethically important licensing con-
ditions, which are aimed at helping the HFEA (and
potentially other international regulators) reduce the pos-
sible risks that accompany the use of these techniques on
humans.
After providing a brief background and scientific over-
view for the current ethical debate surrounding MRTs, this
paper begins by evaluating three central concerns about the
safety of allowing MRTs to be used in clinics: (1) Is it
ethical to use MRTs if other safe alternatives exist? (2)
Would persons with three genetic contributors be put at
risk of psychosocial or physical suffering? and (3) Can
society trust that MRTs will be made available for human
use only once adequate scientific research has taken place,
and that the HFEA’s future licensing framework for clinics
will be robust enough to minimise the risks to future per-
sons born by these techniques? After responding to these
concerns, it is argued that the ethics debate should now be
re-oriented towards recommending ways that regulators
and clinicians can reduce or eliminate the possible health
risks of the first clinical use of MRTs, as this is an area in
urgent need of further attention. One way to reduce the
possible health risks and make the prospective use of
MRTs more ethical, is to place conditions on the circum-
stances under which clinicians are granted licenses for the
clinical use of MRTs. In response to the HFEA’s need to
develop a new licensing framework for the safe and ethical
clinical use of MRTs, two key recommended licensing
conditions are put forward.
The first is that MRTs should only be licensed for
clinical use on the condition that prospective parents are
only granted clinical access to these techniques if they
intend to tell their future MRT-conceived11 children about
the method of their conception by adulthood. The advan-
tages of such a policy would be that MRT-conceived per-
sons would have improved autonomy to care for
themselves and to make more informed reproductive
choices in life. In addition, long-term medical follow-up
and social science research on MRT-conceived persons is
important (Barber and Border 2015; HFEA 2013a) (but not
required) (DH 2014b: p. 42; HFE Regulations 2015) and it
would be unethical to monitor or conduct any research on
these persons once they are adults, if they are not first
adequately informed about this.2
The second condition is that licenses should only be
granted to clinics if sex selection will be used to increase
the likelihood3 that only male embryos will be created and
implanted in the first clinical use of MRTs. Because
mitochondria are maternally inherited, any male offspring
created would be at no risk of passing on any inheritable
health complications associated with their mitochondria
which may have been caused by the use of MRTs. Sex
selection should play an important role in minimising the
transgenerational health risks of any clinical use of MRTs,
at least until more is known about their transgenerational
safety. Much of this paper focuses on UK policy in relation
to MRTs; however the general discussion is relevant to
international policy, in both clinical and research settings.
Background and scientific overview
How mtDNA diseases occur
Mitochondria are cellular organelles which generate energy
for cellular functions. Every mitochondrion carries many
copies of its mtDNA and mutations in the mtDNA are
either created spontaneously during mtDNA replication or
they are maternally inherited. Mutations can be present in
our mtDNA in one of two ways: (1) the mutations exist in
100 % of the mtDNA in our bodies, which is known as
homoplasmy; or, (2) our bodies carry a mixture of healthy
and mutant mtDNA, which is known as heteroplasmy.
Intending mothers with a homoplasmic mtDNA mutation
(e.g. Leber hereditary optic neuropathy, or LHON) will
always pass on the mutation to their offspring (McFarland
et al. 2002: pp. 145–6);4 however, depending on the
mutation, offspring may or may not suffer medical prob-
lems. Determining whether or not someone is likely to pass
1 Conception occurs after MST and before PNT; however, in this
paper I refer to anyone brought into existence with the help of MST or
PNT as being ‘MRT-conceived’.
2 The UK Department of Health (2014b: p. 42) has emphasised the
role and significance of follow-up monitoring and research for MRT-
conceived families, as part of its concluding consultation report on
draft regulations.
3 As discussed later, the wording of ‘increase the likelihood’ is used
here instead of ‘guarantee’, because sperm sorting is what is
recommended and it is not 100 % reliable.
4 An asymptomatic female carrier of a homoplasmic mtDNA
mutation may subsequently pass on the mtDNA mutation with the
prospect of it causing her offspring considerable harm.
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on a heteroplasmic mtDNA disorder to their children is
also not always straightforward. Heteroplasmic mtDNA
mutations (e.g. neurogenic muscle weakness, ataxia, retinis
pigmentosa, or NARP) are among the most common and
while these mutation(s) will always be inherited by off-
spring, the mutation loads5 that are present in those off-
spring will often vary from person to person and depend on
their age. The variability of mutant loads among hetero-
plasmic mtDNA mutant carriers is the result of mosaicism
in the developing embryo, which is caused by genetic
bottlenecks during mitochondrial division.6 The serious-
ness of an mtDNA disorder typically correlates with the
mutant load and the mutation itself. As a result, a consid-
erable amount of uncertainty often exists around the
question of whether or not mothers’ mtDNA muta-
tion(s) will manifest in a harmful way when inherited by
their offspring (Bredenoord et al. 2008a; NCB 2012: p. 26).
Maternal spindle transfer (MST) and pronuclear
transfer (PNT)
It is important to clarify the basic differences between MST
and PNT. The technique of MST involves removing the
maternal spindle (the nuclear DNA) of an intending
mother’s egg with diseased mitochondria, and transferring
that maternal spindle into an enucleated donor egg with
healthy mitochondria. The reconstructed egg is then fer-
tilised with the intending father’s sperm to create a healthy
embryo which can later be transferred into the womb. In
contrast, PNT involves removing the pronuclei (the nuclear
DNA from the intending mother’s egg and intending
father’s sperm) from an embryo carrying diseased mito-
chondria and transferring those pronuclei into an enucle-
ated embryo (created using a healthy donor egg and the
intending father’s sperm) carrying healthy mitochondria.
(Bredenoord et al. 2010: p. 1354).7 The reconstructed
embryo can later be transferred into the womb.
As mentioned in the introduction, no children have been
born via MST or PNT and the full extent of risks associated
with their use is not known (NCB 2012; Baylis 2013;
HFEA 2013a; Knoepfler 2014). Since 2011 the HFEA has
annually published a ‘Review of scientific methods to
avoid mitochondrial disease’ which considers develop-
ments in the safety and efficacy of MRTs. In 2011 the
HFEA reported that a panel of scientific experts concluded
that the ‘evidence currently available does not suggest that
the techniques are unsafe’ (HFEA 2014, p 29). Some have
questioned whether it is ethical to discuss the use of
techniques, such as MRTs, until enough evidence is
available to say that they are safe, (Morrow 2014a) and
have argued that the public should not be satisfied with the
rigour of the HFEA’s research on safety to date (Taylor
2015). Others have pointed out that until a novel medical
technique has been used on a human for the first time, it
almost impossible to be certain of that technique’s risks
and safety for human use (as discussed in NCB 2012: p.
xv). Nevertheless, the HFEA has made clear that it will
continue to monitor ongoing and future research develop-
ments that bear on the safety and efficacy of both tech-
niques and that no licenses for the clinical use of MRTs
will be granted until scientific experts ‘advise the HFEA
that these [research] results are reassuring’ (HFEA 2013a;
p. 29).
Serious safety concerns about medical techniques
involving mitochondrial transfer were initially raised in the
US in 2001 (NCB 2012). Between 1997 and 2001,
approximately 30 babies were born worldwide (but pri-
marily in the US) following the use of an in vitro procedure
known as cytoplasmic transfer (CT), which is a similar but
different technique to MST and PNT (NCB 2012). CT
entails taking cytoplasm containing healthy mitochondria
from a donor’s egg and transferring this cytoplasm into a
recipient’s egg; thus, creating an egg that carries mito-
chondria from both the intending mother and the donor.
This technique was developed as a way of improving the
fertility of the eggs of women who suffer from infertility
problems associated with repeatedly unsuccessful embryo
implantation or inadequate embryo development (NCB
2012). The science behind CT as a treatment is still not
entirely understood; however, by transferring healthy
mitochondria into an egg carrying unhealthy mitochondria,
CT has been described as a way of potentially reducing the
detrimental effects of mitochondrial disease transmission
(NCB 2012). The US Food and Drug Administration
(FDA) banned the use of CT in 2001 (NCB 2012) fol-
lowing reports that one of the fifteen children born from a
US clinic was diagnosed with pervasive developmental
disorder (PDD; Barritt et al. 2000, 2001), and two subse-
quent CT pregnancies from the same clinic were found to
be affected with Turner syndrome (one pregnancy was
5 In basic terms the ‘mutation load’ refers to the ratio of particular
mutant to non-mutant genes that exist in a person’s body. For
example, an mtDNA mutation load of 90 % for mutation ‘X’ would
mean that mutation ‘X’ is present in 90 % of the mtDNA in a body.
6 In the context of heteroplasmic mtDNA disorders, a genetic
bottleneck is created when mitochondria divide during cell division
and each new mitochondrion takes some of the original mitochon-
drion’s mtDNA with it. After division both the old and new
mitochondria replicate the copies of mtDNA they were left with
after division. As a result, there are varying levels of mutant mtDNA
across the mitochondria in our bodies because different ratios of
mutant to healthy mtDNA are passed on each time a mitochondrion
divides. The term ‘mosaicism’ refers to the different levels of mutant
mtDNA that exist between different mitochondria, and ultimately the
different cells that carry them.
7 During PNT it remains unclear if (and how often) a small quantity
of the mitochondria with mutant mtDNA are transferred from the
discarded embryo and into the new embryo.
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terminated and the other resulted in a miscarriage) (Barritt
et al. 2000, 2001; NCB 2012).8 As a consequence, CT fell
into scientific disrepute (NCB 2012). There appears to be
no published follow-up research on the US children born
following CT and there is no central register that is kept as
a record that these children were born this way.
In February 2014 the FDA held meetings to discuss new
developments in the field of MRTs (e.g. MST and PNT)
and how future research could be undertaken in a safe and
ethical way (FDA 2014a, b). The FDA Advisory Com-
mittee found that more scientific research with MRTs was
needed, both on animals and in vitro using human embryos,
before these techniques could be used in a human trial
(FDA 2014b). Therefore, the FDA’s advisory committee
and the HFEA appear to currently share the view that more
research is needed before MRTs are used on humans and
both have an ongoing scientific review process in place.
The Institute of Medicine (IOM), an independent US non-
profit organisation, has recently begun a study commis-
sioned by the FDA to ‘produce a consensus report
regarding the ethical and social policy issues related to
genetic modification of eggs and zygotes to prevent
transmission of mitochondrial diseases’ (IOM 2015). The
first meetings were held in January 2015 and the IOM
committee that is leading the study has indicated that its
report will be ready later in 2015.
In contrast to the US, the UK has had a long-running
ethical debate surrounding the prospect of using MST and
PNT in clinics. In autumn 2011 the NCB launched a con-
sultation on ‘Novel techniques for the prevention of
mtDNA disorders: an ethical review’, which was published
in May 2012. In early 2012 the HFEA also launched a
public consultation entitled ‘Medical frontiers: debating
mitochondrial replacement’ and the findings were pub-
lished in March 2013 in a report entitled ‘Mitochondria
replacement consultation: advice to government’. The
NCB and HFEA reports expressed support for further
research into the safety and efficacy of MRTs, and the
HFEA report also advised the government that there is
general support for permitting MRTs in the UK. The UK
government then drafted regulations to permit the licensed
clinical use of MRTs and the Department of Health held a
public consultation on these draft regulations in early 2014.
Based on the consultation’s findings the Department of
Health decided to put the draft regulations before Parlia-
ment in early 2015 and by February 24th both Houses of
Parliament had approved them. As noted earlier, the HFE
Regulations 2015 are set to come into force in the UK on
29 October 2015 and the HFEA must develop a robust
licensing framework that can review applications from
clinicians wishing to use these techniques.
Ethical challenges to the clinical use of MRTs
The ethical debate surrounding the clinical introduction of
MRTs has generally been centred on three concerns out-
lined earlier about the safety of these techniques. This
section aims to clarify whether or not these concerns are
well-founded and worthy of attention.
Alternatives to MRTs
It has been argued that MRTs are not an ethical means of
reproduction so long as questions remain about their safety
and other safe means of reproduction already exist (Baylis
2013: pp. 532–3).9 For example, the use of donor eggs and
embryos to conceive children is known to be safe following
years of clinical use. In contrast, PNT and MST have not
been used on humans to prove their safety. Until MRTs are
first used on humans to demonstrate their safety, the use of
donor eggs and embryos will continue to be viewed by
many as a safer way of having children. A report by the
NCB (2012: p. 67) discusses how some have objected that
even using MRTs on a small number of humans would be
unethical. This objection is based on the view that it will
always be unethical to create a human with MRTs so long
as risks exist and other safe alternatives are available.
However, this objection raises an important question: can
safe alternatives (e.g. using donated eggs or embryos) offer
the same reproductive benefits that some prospective par-
ents want and that MRTs promise?
Unlike the use of donor eggs or embryos, MRTs provide
a genetic link between mothers and their children. Some
may feel that it is important to have a genetic link with
their future child and that having this genetic link out-
weighs most disadvantages (e.g. health risks and high
financial cost) associated with MRTs; thus, for these
intending mothers using egg or embryo donation is not a
suitable alternative. Therefore, what other safe alternatives
could allow an intending mother to have a child to whom
they are genetically linked?
Pre-implantation genetic diagnosis (PGD) and prenatal
diagnosis (PND) are two techniques that can sometimes be
used as alternatives to MRTs, in order to help intending
mothers have healthy children to whom they are geneti-
cally related. The process of PGD involves removing a cell
from an embryo in order to test that embryo for the
8 PDD is a spectrum disorder and refers to a group of autism-related
disorders (NCB 2012). Turner Syndrome affects females and can
involve a number of symptoms, such as: lymphedema (swelling),
sterility, and hearing loss.
9 This point has also been discussed in detail by the NCB (2012:
pp. 57–87) and Bredenoord and Braude (2011).
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presence of harmful concentrations of mtDNA mutations
that could result in a mtDNA disease. This procedure is
conducted prior to the embryo being transferred into the
uterus and can be used to select an embryo that is con-
sidered to be the least likely to result in a person that will
suffer from a mtDNA disease. Similarly, PND is used to
test the cells of a fetus to determine if it is likely to have a
mtDNA disease based on the concentration of mutant
mtDNA that is present in its cells during prenatal devel-
opment. Prospective mothers can then abort the pregnancy
if they do not want to give birth to a child who is likely to
have a mtDNA disease.
However, the predictive uncertainty associated with
these techniques means that they are not always reliable
methods of avoiding the creation of children who will
suffer from mtDNA diseases (Bredenoord et al. 2008a).
PGD and PND are of no use for intending mothers with
homoplasmic mtDNA diseases because their eggs and
embryos will always have a 100 % mutation load of dis-
eased mtDNA (Braude and Lovell-Badge 2014). For
intending mothers with heteroplasmic mutations, PGD may
also reveal that it is impossible for them to produce eggs
with safe levels of mutant mtDNA. Finally, any female
offspring born following PGD or PND may also be liable to
pass on mtDNA diseases to their offspring, due to the
ongoing presence of some inherited mutant mtDNA in their
bodies (Bredenoord et al. 2008b).
Therefore, in some cases, PGD and PND can help
intending mothers have children to whom they are genet-
ically related and who will not suffer from mtDNA dis-
eases. For other intending mothers PGD and PND will not
be viable alternatives to help them have healthy children.
This latter group of intending parents will be left with the
remaining options of either not reproducing or waiting for
MRTs to become clinically available. In other words,
MRTs may be the only chance for some intending mothers
to have children to whom they are genetically related.
Evidence suggests that rather than abstain from reproduc-
ing, some parents would be willing to use MRTs if they
become clinically available (NCB 2012: p. 61). However,
some (Baylis 2013; Taylor 2015) argue that existing safety
concerns about MRTs makes them an unethical reproduc-
tive option for anyone to choose (even if this means not
having children). Therefore, what are these safety concerns
and how serious are they?
MRT safety and offspring with three genetic
contributors
One of the most common safety concerns associated with
MRTs is that they will create persons with three genetic
‘parents’ and that having three genetic ‘parents’ could
cause a person to suffer (NCB 2012: pp. 32–6; Baylis 2013:
p. 522; Donnelly 2014; Gallagher 2014).10 However, this
claim requires clarification. There is no reason that any
particular parenting arrangement will follow from the use
of MRTs (Johnson 2013) and it is misleading to suggest
that children conceived by MRTs will have three parents.
The wording of ‘three genetic parents’, has often been used
by the media and researchers to describe how MRT-con-
ceived children will have three genetic contributors (Don-
nelly 2014; Caldwell 2015). It is this link between the use
of MRTs and the creation of children with genetic contri-
butions from three individuals that has caused ethical ten-
sions to arise. Two predominant safety concerns exist about
MRT-conceived children having three genetic contributors.
The first concern is that MRT-conceived children could
experience some form of psychosocial suffering as a result
of having genetic ties to three persons (as discussed in
NCB 2012: p. 71).11 For example, one worry is that chil-
dren might have a troubled relationship with their parents
or struggle to develop their identity, as a result of knowing
they share a mitochondrial genome with a donor. Currently
no empirical evidence exists about the psychosocial well-
being of MRT-conceived children, which makes it difficult
to determine if any of the above risks will materialise.
However, empirical evidence does exist from social sci-
ence studies on children conceived via gamete donation.
This psychosocial evidence does not indicate that gamete
donor-conceived children experience problems with their
identity development, but it does show that donor-con-
ceived children have functional relationships with their
parents (Ilioi and Golombok 2014; Shelton et al. 2009).
Evidence from families created by gamete donation can
provide valuable insight into the psychosocial development
of children who share genetic ties with others who do not
necessarily occupy parental roles in their lives.12 When
discussing the prospect of creating children using MRTs,
the existing evidence about children conceived via gamete
donation should help to allay any concerns about how
vulnerable these prospective children might be to suffering
from psychosocial problems; thus, at this time it would be
unreasonable to prohibit the use of MRTs, on the grounds
of contestable safety claims such as these.
The second concern is that the physical wellbeing of
MRT-conceived children could suffer because they have
10 MRT-conceived offspring would have ties through their nuclear
genome to two persons and a tie through their mitochondrial genome
to a third person.
11 The term psychosocial refers to persons’ psychological and
behavioural development in relation to their social environment.
12 The UK Department of Health (2014b) has emphasised the
importance of carrying out similar research in the future on the first
generation of MRT-conceived persons.
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three genetic contributors.13 For instance, one possible risk
is that a donor’s mtDNA could potentially fail to function
properly with the nuclear genes contributed by the
intending parents (HFEA 2013b; Knoepfler 2014; Morrow
2014b).14 If donor mtDNA did prove to be incompatible
with the nuclear DNA of the intending parents, the
resulting child might suffer from health complications.
Another concern is that during PNT or MST, some of the
intending mother’s diseased mitochondria could be inad-
vertently transferred into the ‘healthy’ embryo or egg,
respectively. While the presence of a very small amount of
diseased mtDNA may not be a health risk for the carrier, it
could pose a health risk (i.e. an mtDNA disease) for that
carrier’s offspring. Therefore, it appears that MRT-con-
ceived children could be exposed to some risks to their
physical wellbeing. In light of these possible risks, how, if
at all, can the clinical introduction of MRTs proceed in an
ethical manner?
The importance of pre-clinical safety research
and risk reduction in clinical settings
With the above health risks in mind, there are two key
responsibilities that must be satisfied in order to help make
the clinical introduction of MRTs as ethical as possible.
The first is to ensure that a rigorous schedule of pre-clinical
safety testing takes place for MRTs before they are
permitted for human use. The second is to make sure that
any clinical use of MRTs includes adequate safeguards to
minimise the health risks to future persons wherever pos-
sible. However, have both of these responsibilities been
adequately accounted for in discussions about MRT
research, policy and regulation so far?
The first responsibility seems straightforward; however,
some distrust exists towards research on assisted repro-
ductive technologies (ARTs) because there is a long history
of some ARTs being introduced into medical practice
without having gone through a rigorous schedule of testing
or a clinical trial (Dondorp and de Wert 2011; Harper et al.
2011). For example, as recently as 1990, the first child was
born after being conceived via intra-cytoplasmic sperm
injection (ICSI), without much experimental research being
conducted beforehand (Harper et al. 2011: p. 3). In con-
trast, MRT research has been subject to considerable
HFEA oversight, scientific scrutiny and public debate. A
schedule of research milestones has been set out by regu-
lators and these milestones must be met in order to ensure
the efficacy and safety of MRTs, before they can be
licensed for use in a clinical setting (HFEA 2013a: p. 13).
Nevertheless, some critics have argued that the HFEA
review process (including the consultation) was method-
ologically flawed, that it misrepresented public opinion and
that it failed to include key research requirements and
evidence (Taylor 2015). The HFEA’s scientific review is
ongoing, and therefore it is difficult to say with certainty
that any particular research or evidence has been defini-
tively discounted from future consideration at this point in
time. The HFEA’s consultation also had an independent
oversight group to ensure that the process of the consul-
tation was balanced. Furthermore, an independent review
of the HFEA’s consultation on MRTs found that some of
the report’s methodologies and reporting could be
improved, but that overall the process and the final report
was sound (Watermeyer and Rowe 2013). Therefore, while
some distrust towards ARTs lingers in society, others trust
that the safety of MRTs will be thoroughly researched prior
to being approved for licensed clinical use on humans.15
Importantly, the HFEA must continue working to cultivate
and foster the trust of both its sceptics and supporters while
it continues to review how MRTs can be licensed for
clinical use in the future.
While preparations have been made by the HFEA to
fulfil the first responsibility mentioned above, there appears
to have only been a limited discussion, so far, about how to
satisfy the second one. It is therefore essential that the
ethical debate about MRT safety is re-oriented to prioritise
and foster discussions about which precautionary measures
13 In this debate there has been considerable disagreement about
whether or not MRTs should be considered a form of germ-line
modification or a form of genetic modification. The UK Department
of Health (2014a) and the NCB (2012) argue that because MRTs only
introduce new mtDNA and do not modify the nuclear genome, it is
incorrect to describe MRTs as a form of genetic modification and that
it is in fact a form of germ-line modification. Meanwhile, Baylis
(2013: p. 533) and Knoepfler (2014) interpret the replacement of the
intending mothers’ mitochondria (and the genome they carry) with a
donor’s mitochondria, to be a form of genetic modification. In the
end, if the potential health outcomes of using MRTs is our only
concern, then the question of whether or not PNT or MST are forms
of germ-line modification or genetic modification, is actually a moot
point because alone this distinction will not reveal anything about
whether or not the science is safe.
14 This point was discussed and debated at length in a UK House of
Commons Science and Technology Committee (2014) meeting on
evidence about mitochondrial donation. It was also raised in an article
by Reinhardt et al. (2013) and responded to by the HFEA (2013b) in a
statement which offers a technical discussion of the safety concerns.
Ted Morrow has also been concerned about the safety of possible
mismatches between nuclear DNA and mtDNA and that MRT
regulations and research to date have not adequately accounted for
this concern (Morrow 2014b). The HFEA agrees that mtDNA and
nuclear DNA interactions are still poorly understood and risks may
exist as a result of mismatches (and that perhaps some form of attempt
at matching DNA types is needed in the future, when possible);
however, it is not clear that the risks associated with mismatches
between the mtDNA and the nuclear DNA are going to be greater
than any other form of human reproduction and it is not clear that
MRTs will carry any heightened risks (in this respect) (HFEA 2013b).
15 For further discussion see Braude and Lovell-Badge (2014) in
conversation with Knoepfler (2014).
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should be put in place when designing a framework for
licensing these techniques, in order to minimise health
risks. Next, this paper identifies two recommended condi-
tions that would help to minimise possible mitochondria-
related health risks (i.e. those mentioned in previous
sections).
The importance of ‘disclosure’ to persons created
via MRTs
The first recommended condition is that prospective par-
ents should only be granted licensed access to MRTs in a
clinic if they intend to tell their children, or ‘disclose’,16
about their origins (i.e. being MRT-conceived). One benefit
of disclosure is that it would save some children from the
stress and anxiety of worrying about suffering from the
same mtDNA disorders as their mothers.17 However, some
prospective parents may not wish to disclose to their future
MRT-conceived children, as this is also the case with some
parents who have children conceived via gamete donation
(Readings et al. 2011; Blake et al. 2010). Some prospective
parents may prefer non-disclosure because they feel that
their use of MRTs is a matter of personal privacy, which
they feel their children have no claim to know about.
Others who prefer non-disclosure may simply tell their
children that they were conceived using IVF, but leave out
the fact that an MRT was used. Research has shown that
some parents with children conceived via gamete donation
have employed similar strategies for non-disclosure and it
is possible that some parents with MRT-conceived children
will prefer to do the same (Daniels 1997; Freeman 2015;
NCB 2013; Readings et al. 2011).
It is important that the first generation of persons con-
ceived via MRTs are disclosed to. Disclosure is important
for at least two reasons: (1) the MRT-conceived person’s
own medical welfare; and (2) knowledge of having been
MRT-conceived enables persons to report any medical
problems back to clinicians and researchers for the sake of
the wellbeing of future generations who might be con-
ceived via MRTs. Clinicians should only be licensed to
treat prospective parents with MRTs if they intend to dis-
close to their children. Therefore parents’ intention to
voluntarily disclose to their future MRT-conceived chil-
dren should constitute one of the conditions for licensing a
clinic to use MRTs.
Disclosure to the first generation of persons conceived
via the initial clinical use of MRTs is an important part of
safeguarding them from possible MRT-related health risks.
For example, the HFEA (2013a: p. 26) also supports the
recommendation that future MRT-conceived persons be
disclosed to at an early age. Excluding prospective parents
from accessing MRTs on the grounds that they do not
intend to disclose is justifiable on the basis that: (1) initial
access to MRTs will most likely be a limited resource18;
and (2) it is permissible for the HFEA and clinicians to take
a welfare-maximising approach to managing the public
health of this research population, which involves only
selecting prospective parents who will likely have children
who the clinicians believe will fare the best. Knowing one
was conceived with an MRT is important when it comes to
having an autonomous capacity to care for one’s own
wellbeing, especially as an adult. For example, it is
important that someone knows that they were conceived
with an MRT so that they can inform others (e.g. medical
practitioners) who might be caring for their health (e.g. if
they are suffering from a health complication related to
their mitochondria). Allowing prospective parents to access
MRTs, who are not intending to disclose, would increase
the possibility that some MRT-conceived children could be
deprived of knowing an important part of their medical
history. Trying to ensure that future MRT-conceived per-
sons are disclosed to is essential to improving the ethical
use of these techniques, as this disclosure will further
enable persons to properly care for their own health over
the course of their lives.
In addition, the safety of future generations conceived
via MRTs is dependent on disclosure to the first generation.
To gain a robust understanding of the safety of MRTs,
clinicians need to be able to gather information about the
health outcomes of the first generation conceived with
MRTs, for as long as possible. For example, the UK
Department of Health has recently stated that enabling
MRT-conceived persons to be followed-up ‘‘…is vital if
the impact of the mitochondrial donation techniques is to
be fully understood’’ (although, follow-up research will not
be required) (DH 2014b: p. 42). In order for clinicians to be
able to potentially continue gathering information about the
health outcomes of MRT-conceived persons as adults, this
cohort will need to have been disclosed to. Otherwise they
16 Here the act of telling someone that they were MRT-conceived is
referred to as ‘disclosure’.
17 If MRT-conceived children are not disclosed to, it is possible that
they could suffer from the stress and anxiety of thinking they will
inherit a debilitating mtDNA disorder from their mothers. A recent
NCB report (2012) highlighted a similar case in the context of sperm
donor conception, where a child grew up with the stress and anxiety
of thinking she might fall ill from an inheritable disorder from her
father. The child was not genetically related to the social father;
however, because of non-disclosure by her parents she suffered the
psychological harm that came with the false belief that she may have
inherited a debilitating condition.
18 There are several reasons for this. The first is that few clinics are
likely to be licensed to use MRTs. The second is that few clinicians
will initially have adequate training to use MRTs.
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will never understand the nature of the medical monitoring
that may have been part of their lives so far,19 and will not
realise how they can help future generations by remaining
engaged with clinicians.
However, the complexities of disclosure in families
should not be understated. Disclosure is typically a process
of explanation and a topic of ongoing dialogue between
parents and children, and there is usually no clear end date
(Blake et al. 2010; Readings et al. 2011; Freeman 2015).
Disclosure is not typically a one-off event and the infor-
mation shared during the initial disclosure may not be
something the children can understand the meaning of until
they have reached a stage (e.g. adolescence) of adequate
psychological development (Blake et al. 2010; Readings
et al. 2011; Freeman 2015).20 Given the complexities of
disclosure in families, it will be important that clinics and
the HFEA ensure that parents have access to relevant
counselling and resources (e.g. disclosure aids in the form
of children’s books).
Possible objections to the recommendation to use
parental intent to disclose as a licensing condition
The first objection to only allowing clinical access to
MRTs for parents who intend to disclose might be the
following: in the UK prospective parents are not denied
access to donor gametes if they do not intend to disclose to
their future donor-conceived children, so why should
prospective parents accessing MRTs in a clinic be treated
any differently? The answer is that because this will be the
first clinical use of MRTs, clinicians may be unsure about
whether or not the resulting child could still suffer from an
inherited mtDNA disorder or some other MRT-related
health complication. Therefore, regulators and clinicians
are ethically bound to ensure that the limited number of
children created via the first use of MRTs have the best
chance of being disclosed to, so that they can be aware of
these possible health risks. In contrast, robust medical
evidence exists regarding the wellbeing of donor-con-
ceived children; thus, there is less medical motivation for
disclosure in these cases and they are not comparable to
cases of MRT conception in this respect.21
The second objection is that prospective parents wishing
to access MRTs could say that they intend to disclose and
then once the child is born they could simply break off
contact with the clinic and choose to never disclose to the
child. This is a difficult challenge that any clinic might face
and the UK Department of Health has made clear that ‘‘the
regulation-making power does not provide the scope to
include this (i.e. a requirement for follow-up research)
within the regulations and, in any case, there would be
difficulties around placing a legal obligation on families to
participate in follow-up research’’ (2014a: p. 24) or any
clinical monitoring for that matter. However, offering
counselling prior to using MRTs may also help parents to
better understand the risks of non-disclosure to their chil-
dren in this instance, as well as the potential health risks of
breaking off contact with medical experts. In any event,
having a small number of parents changing their minds
after the use of MRTs and ultimately not disclosing is
preferable to making disclosure mandatory. This is true not
only because it is difficult to enforce mandatory disclosure
from a practical point of view (as mentioned above) but
also because it would be challenging to legally justify such
interference in the private and family life of the families
created via MRT use.
For example, enforcing a mandatory disclosure policy in
the case of MRT use would likely contravene Article 8 of
the European Convention of Human Rights (ECHR), which
states:
1. Everyone has the right to respect for his private and
family life, his home and his correspondence.
2. There shall be no interference by a public authority
with the exercise of this right except such as is in
accordance with the law and is necessary in a
democratic society in the interests of national security,
public safety or the economic wellbeing of the country,
for the prevention of disorder or crime, for the
protection of health or morals, or for the protection
of the rights and freedoms of others.
The question of whether an interference is justifiable
under Article 8(2) involves a three-step analysis which
addresses whether the measure is in accordance with law,
has a legitimate aim, and is necessary.22 In turn, the third
element involves a three-step assessment, established in
19 For example, their families may have simply told them they were
being researched for a reason other than having been conceived via an
MRT.
20 Some parents may choose to disclose to their children from a very
young age (and continue to discuss this with them from that time
onward) so that there is never a time when their children were not told
about being MRT-conceived (in some sense); however, other parents
may wait until the ‘right time’ (e.g. early adolescence) to disclose to
their children because the parents feel that they should wait to
disclose at a stage of their children’s lives when they are more capable
of grasping the meaning of being donor-conceived. For a discussion
on the complexities of disclosure, see: NCB (2013).
21 Clinics are always likely to screen gametes for inherited genetic
disorders (e.g. Huntington’s disease) regardless of whether or not
MRTs are likely to be used. Therefore, the threat of future persons
inheriting genetic disorders as a result of IVF in a clinic is always
likely to be extremely low.
22 See e.g. A, B & C v Ireland, App No 25579/05, (2011) 53 E.H.R.R.
13 paras 219–242.
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Sunday Times v United Kingdom,23 namely whether there
is a pressing social need for the interference, whether it is
proportionate to the legitimate aim and whether there are
relevant and sufficient reasons for it. At this point in time,
given the stringency of the test to justify interference under
Article 8(2), justifying compulsory legal disclosure would
require more robust scientific evidence about the possible
risks associated with being MRT-conceived than is cur-
rently available.
Sex selection to reduce health risks to future
generations
There is uncertainty about the safety of MRTs for future
generations, and an ethical responsibility therefore exists to
employ a safety strategy in clinical practice, which would
help reduce transgenerational health risks. One concern is
that during PNT or MST, small amounts of mitochondria
with harmful mtDNA mutations could accidentally be
transferred, along with the maternal spindle or pronuclei,
and deposited into the healthy egg or embryo, respectively
(Bredenoord et al. 2010: p. 1355; NCB 2012: p. 80).
Having such a small amount of diseased mitochondria
would be unlikely to cause any suffering to the person
created via the MRT. However, if a person carrying very
low levels of unhealthy mtDNA has children, there is a
possibility that a mtDNA disease could manifest in the
those offspring. Because the mitochondrial genome is
maternally inherited, clinicians applying to the HFEA for a
license to use MRTs should be required to use sex selection
techniques to select for male offspring (whenever possible)
(Bredenoord et al. 2010)24 in order to reduce mtDNA-re-
lated transgenerational health risks.25
Traditionally, PGD has been the method by which sex
selection has been carried out on embryos. However, in
2013 the HFEA advised the UK government that sex
selection via PGD is an impractical safeguard because it
requires additional manipulation of the embryo (HFEA
2013a: p. 17). If PGD for sex selection is not an option,
then clinicians could use sperm sorting technology instead.
Sperm sorting using ‘flow cytometry’ is a process in which
a fluorescent chemical binds with the DNA of sperm cells
and a laser is then used to sort ‘female’ sperm cells with
X-chromosomes from ‘male’ sperm cells with Y-chromo-
somes. A laser is able to detect and sort the two cell types
because X-chromosome bearing cells appear more
fluorescent than Y-chromosome bearing sperm cells,
because the former have more DNA for the fluorescent
chemical to bind to. However, this type of sperm sorting
can only be used by clinics which are licensed by the
HFEA to use it with patients for medical reasons.
The main drawback of sperm sorting is that it is not
100 % reliable. One sperm sorting technology is
MicroSort and it will correctly sort sperm into samples
that are on average 91 % pure ‘female’ sperm and 74 %
pure ‘male’ sperm (Microsort 2014). It is possible that
these figures might improve as sperm sorting technologies
are refined in the coming years. However, even if clinicians
used sperm sorting to successfully create male embryos
only 74 % of the time, this would still represent a potential
24 % reduction of mitochondria related transgenerational
health risks in a clinical trial (assuming that the average
‘natural’ likelihood of having a female or male child is
about 50 %). Clinicians should therefore use sperm sorting
for sex selection to create the first generation of persons
with MRTs, as this would help to reduce risks to future
generations.
However, in a report on MRTs published by the NCB,
Ken Taylor and Erica Haimes, responding to the Nuffield
Working Group’s call for evidence, identified several
objections to the prospect of using sex selection for the first
clinical use of MRTs (NCB 2012: p. 80). First, they argue
that it would be unacceptable to create an ‘experimental
group’ of male offspring who would have to be monitored
over the course of their lives (NCB 2012: p. 80). Taylor
and Haimes express concern that as a result of sex selection
there would be a generation of boys conceived via MRTs
who would be ‘experiments’ and would ‘‘…live with
uncertainty about their future health, beyond that normally
experienced’’ (NCB 2012: p. 80). They add that these
individuals would need to be considered healthy before the
next generation of children (including females), could be
created with MRTs (NCB 2012: p. 80). Second, they argue
that the selection of only males would be based on the
assumption that the long-term undesirable outcomes asso-
ciated with MRTs would not be attributable to anything
beyond mitochondria (NCB 2012: p. 80). On the basis that
this particular assumption could be wrong, they argue that
researchers cannot justify only exposing male offspring to
the potential risks of MRTs (NCB 2012: p. 80). Finally,
they suggest that the mere fact that sex selection is being
considered as a means of limiting risk, is itself indicative
that not enough is yet known about whether MRTs are safe
(NCB 2012: p. 80). The above are all important points
worth considering.
Consider the objection that it would be unethical to
create an experimental group of male offspring who would
be studied for a large part of their lives. As noted earlier, it
would be valuable to monitor MRT-conceived persons for
23 Sunday Times v United Kingdom (1979) 2 E.H.R.R. 245.
24 Sex selection technology such as sperm sorting is not 100 %
reliable.
25 Bredenoord et al. (2010) were some of the first to give a detailed
account of the merits and weaknesses of using sex selection
(including sperm sorting) to manage risks in conjunction with the
use of MRTs.
The ethical challenges of the clinical introduction of mitochondrial replacement techniques 509
123
as long as possible in order to be able to record any adverse
results that might emerge about MRTs (DH 2014b). But
while parents who have children via MRTs may feel
morally compelled to have their children monitored by
clinicians, doing so would ultimately be their own choice
because compulsion of this obligation would be difficult
for a range of legal, policy and practical reasons (DH
2014b). That said, any voluntary clinical monitoring pro-
gram for MRT-conceived persons would be of value to
parents wishing to care for the wellbeing of their children.
In addition, it is unclear how demanding the role of being
monitored by clinicians might actually be for children or
adults. It might be that being clinically monitored is not
very demanding. Nevertheless, at the age of 18 anyone who
was initially enrolled in such a monitoring program
because they were conceived via an MRT could opt out if
they wished. Before the age of 18, they may be able to do
so regardless of their parents’ desires for them to remain
involved, depending on how serious the risks of non-par-
ticipation were deemed to be at the time.26 MRT-conceived
persons could also suffer from the uncertainty of not
knowing if they will have future health complications as a
result of having been MRT-conceived. While all of the
above concerns are ethically relevant for researchers to
keep in mind, none of these concerns are specific to the use
of sex selection. In fact, none of these concerns would be
resolved if sex selection were not used and if the children
conceived via MRTs were of both sexes. The demanding-
ness of being born into a life which involves clinical
monitoring (or any form of follow-up programme) is
unaffected by whether or not the offspring are solely male,
and as a result this argument is not a good reason for not
recommending the use of sex selection as a licensing
condition for the first use of MRTs in clinics.
The second objection to sex selection claims that
because researchers are not yet certain that mitochondria
will be the root cause of any possible undesirable side
effects following the use of MRTs, we therefore cannot
justify only selecting for male children to be born in order
to safeguard against this ‘assumed’ risk. This is an
interesting argument, but it neglects several other impor-
tant points that make sex selection an important research
requirement. As noted above, evidence to date has indi-
cated that there could be a genuine risk that during the
procedure of using an MRT, diseased mitochondria could
be unintentionally transferred into a healthy egg or embryo.
If the evidence continues to suggest that there could be a
mitochondria-linked health risk to future generations, then
sex selection would remain an important safeguard for
clinicians to employ.
The third objection claims that if sex selection is a
necessary safety precaution for clinical MRT use at this
point in time, then this is indicative that these techniques
should not be used because not enough is known about
their safety. However, even if the recommendation of sex
selection does trigger concerns from critics about the safety
of MRTs, the other way of looking at this is that the
absence of this recommendation should also trigger con-
cerns about the lack of an important safeguard for the
wellbeing of future generations. It would be a serious
mistake to make broad assumptions about the overall safety
of the clinical use of MRTs on the basis that sex selection
also happens to be a viable method of safeguarding future
generations from suffering mitochondria-linked disorders.
Any appraisals of the safety of MRT use should instead be
based on a full review of the evidence, rather than specu-
lation that is premised on the proposal of an individual
clinical intervention such as sex selection.
Considering how few prospective parents would likely
be granted clinical access to MRTs (the chances are that it
would be\10 cases each year), it is hard to imagine how
bringing only males into existence would harm society or
cause suffering to the prospective parents or children (DH
2014a: p. 38). The small number of licenses granted by the
HFEA for MRT use would mean that the use of these
techniques would not have an impact on sex ratios in the
general population, especially considering that the rarity of
mtDNA disorders may entail the recruitment of individuals
from a broad geographic area. As sex selection would only
be used for the sake of safety, it could hardly be construed
as an expression of sexism. Creating a cohort of MRT-
conceived children who are all male would of course also
mean that only evidence on the welfare of males could
potentially be gathered by any form of future social science
research or clinical monitoring conducted on this cohort.
Even so, this would be a worthwhile limitation if it further
demonstrates that the techniques are generally safe and if it
provides additional confidence that MRTs will most likely
be safe to use for both the creation of females and any
generations of future offspring they may have.
Some countries, such as the UK, do not permit sex
selection for the sake of avoiding the creation of carriers
who will not suffer from inheritable diseases but may pass
26 Adolescents are presumed competent by virtue of the Mental
Capacity Act (2005), s. 1(2). The Act applies to anyone over 16 (s.
2(5)). However, case law shows that the courts are reluctant to let
adolescents refuse medical treatment where this may result in serious
harm to them. See especially Re W (A Minor) (Medical Treatment:
Court’s Jurisdiction) [1993] Fam 64 and the judgments of Balcombe
and Nolan L.J.J. That case concerned, in part, interpretation of the
Family Law Reform Act (1987). 8(3): the court held that doctors can
rely on a parent’s consent in the face of a refusal by an adolescent of
16/17 years (where that would result in serious harm to them). When
a person reaches the age of 18, the courts no longer intervene in this
way. In addition, note that the legal presumption of a lack of
competence under 16 is rebuttable by virtue of the decision in Gillick
v West Norfolk & Wisbich Area Health Authority [1985] UKJL 7.
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them on to their offspring. Under Schedule 2 of the Human
Fertilisation and Embryology (HFE) Act (1990) (as
amended by the HFE Act 2008):
1 (1) A licence under this paragraph may authorise any
of the following in the course of providing treatment
services—
…
(b) procuring, keeping, testing, processing or dis-
tributing embryos…
1ZA (1) A licence under paragraph 1 cannot authorise
the testing of an embryo, except for one or more of the
following purposes—
…
(c) in a case where there is a particular risk that any
resulting child will have or develop—
(i) a gender-related serious physical or mental
disability,
(ii) a gender-related serious illness, or
(iii) any other gender-related serious medical
condition, establishing the sex of the
embryo…
(2) A licence under paragraph 1 cannot authorise the
testing of embryos for the purpose mentioned in sub-
paragraph (1)(b) unless the Authority is satisfied—
(a) in relation to the abnormality of which there is a
particular risk, and
(b) in relation to any other abnormality for which
testing is to be authorised under sub-paragraph
(1)(b),
that there is a significant risk that a person with the
abnormality will have or develop a serious physical or
mental disability, a serious illness or any other serious
medical condition.
(3) For the purposes of sub-paragraph (1)(c), a physical
or mental disability, illness or other medical condition is
gender-related if the Authority is satisfied that—
(a) it affects only one sex, or
(b) it affects one sex significantly more than the other.
What constitutes a significant risk in the realm of
mtDNA disease can be difficult to determine. According to
the HFEA Code of Practice, decisions about what consti-
tutes ‘significant risk’ are left up to the judgement of
clinicians in the case of PGD (HFEA 2014: §10.6). Fur-
thermore, the Department of Health (2014a: p. 46) has
indicated that any future use of MRTs on humans is likely
to be approved for licensing on a case-by-case basis.
Since, as noted earlier, PGD for sex selection is not an
option, we must consider the regulation of sperm sorting.
As a matter of interpretation of the HFE Act (1990) (as
amended), sex selection via sperm sorting must be licensed
by the HFEA before it can be used by a clinic (HFE Act
1990: Schedule 2, } 1ZB(3)).27 Given the terms of the
current sex selection regulations regarding embryos just
discussed, the HFEA would be unlikely to consider a low
level mtDNA mutation carrier to be at a ‘particular’ or
‘significant’ risk of developing a ‘serious physical or
mental disability, a serious illness or any other serious
medical condition’ (as required under the HFE Act 1990:
Schedule 2, } 1ZA(2)). Nevertheless, the use of sex
selection using sperm sorting in conjunction with MRTs
could be made legally permissible if the recently approved
HFE Regulations 2015 for MRTs were amended (and the
amendments were then passed into law by Parliament). In
the HFE Regulations 2015 (which amend the HFE Act
1990, as amended) an amendment could be made in Part 2,
Section 9, titled ‘‘Supplemental provision-licenses’’, to
include an additional provision that would allow for the use
of sex selection to avoid or reduce the transmission of
mtDNA diseases in the context of MRT use on humans.
The amendment of the regulations may appear to be a
demanding recommendation. However, permitting sex
selection would assist clinicians to fulfil their ethical duty
to prospective parents and their future offspring, by min-
imising the possible transgenerational health risks of using
MRTs. Regulators also have a responsibility to enable
clinicians to conduct safe clinical procedures and in this
instance that means permitting the licensed use of sperm
sorting for sex selection.
Conclusion
The aim of this paper has been to clarify and critically
assess some of the central ethical concerns about the safety
of MRTs for clinical use and to then move the debate
forward by focusing on two key recommended conditions
that should be met in order for the HFEA to grant clinicians
a license to use MRTs on humans. These recommended
conditions will help to reduce the potential health risks of
MRTs. The future human use of MRTs has been dismissed
by some as ethically impermissible because other safe
alternatives, such as egg donation, PGD and PND, already
27 Section 10.19 of the HFEA Code of Practice (2014) also states ‘‘If
sperm is sorted for medical reasons to create (or maximise the chance
of creating) embryos of a particular sex for medical reasons, patients
should be given information about the process, procedures, possible
risks and the experience of the clinic in doing the procedure.’’ This is
helpful because it sheds light on the best clinical practices for sperm
sorting and it also suggests that Schedule 2, paragraph 1ZB(3) of the
HFE Act (1990) (as amended) is indeed referring to the licensing of
sperm sorting as one of the ‘‘other practices designed to secure that
any resulting child will be of one sex rather than the other…’’.
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exist. However, for some intending parents who want
offspring to whom they are genetically related, but who
face the prospect of passing on a mtDNA disease, no other
reproductive alternatives exist beyond the prospect of using
MRTs.
Two types of safety concerns about offspring having
three genetic ‘parents’—or more accurately, three genetic
contributors—regularly emerge in discussions about the
clinical use of MRTs. The first concern is that MRT-con-
ceived offspring could experience some form of psy-
chosocial suffering, but this concern is not persuasive
because existing empirical evidence suggests that persons
in similar situations (e.g. gamete donor conceived persons)
usually experience average psychosocial wellbeing (Free-
man 2015; NCB 2013). The second concern is that the
physical wellbeing of MRT-conceived persons could suffer
as a result of mitochondria-related health complications
(e.g. mtDNA that is incompatible with nuclear DNA or low
levels of mitochondria with diseased mtDNA). Concerns
regarding health risks to future MRT-conceived persons
should be taken seriously and action should be taken by
researchers, regulators and clinicians to reduce such risks
in at least two ways: (1) adequate pre-clinical safety testing
of MRTs needs to be carried out; and (2) the framework for
licensing the first clinical use of MRTs should be well-
constructed with the aim of reducing or eliminating health
risks wherever possible. While the HFEA has a schedule of
pre-clinical research milestones in place to test the safety
of MRTs, comparatively little progress has been made in
terms of discussing how the licensing conditions and
framework for the first clinical use of MRTs should be
designed in order to reduce MRT-related health risks.
This paper recommends two licensing conditions that
should become part of any future licensing framework used
by the HFEA to permit the clinical use of MRTs with
humans. The first recommended licensing condition is that
any child conceived following the use of a MRT should be
disclosed to by adulthood, either by their parents or by a
member of the clinic (e.g. clinician or counsellor). In fact,
prospective parents who do not intend to disclose, should
be excluded from accessing MRTs in clinics. One advan-
tage of this recommendation is that the MRT-conceived
children’s autonomy will be improved as a result of
knowing a key piece of their medical history, which they
can use to help care for themselves or to inform others (e.g.
physicians) to help care for them if a MRT-related health
complication arises. In addition, MRT-conceived persons
will be better informed about the potential health risks of
their own reproductive decisions (e.g. will their children
inherit a mtDNA disease?). A second advantage is that if
children are disclosed to they will then be aware of the
nature of any possible research their parents may have
become involved in and at the age of 18 researchers will be
in a better position to talk with them about continuing with
a programme of medical monitoring or social science
research. Disclosure better enables the long-term medical
monitoring of MRT-conceived offspring, and both those
being monitored and future generations will benefit from
any findings discovered in this initial monitoring or
research.28 This recommendation for disclosure should be
incorporated into the guidance of the HFEA Code of
Practice (2014) and it should be included in any additional
guidance documents on the clinical use of MRTs produced
by either the HFEA or the UK Department of Health.
The second recommended licensing condition is that
MRTs should only be permitted for clinical use if clinicians
agree to use sex selection, with the aim of only creating
male embryos in order to reduce or eliminate the likelihood
of transgenerational mitochondria-related health risks.
Objections exist to this recommendation; however, none of
them outweigh the risks that are reduced by sex selection.
It is unlikely that sex selection would be licensed for MRT
research under the current law (i.e. Schedule 2 of the HFE
Act 1990, as amended 2008), and therefore the HFE
Regulations 2015 should be amended to include a provi-
sion that permits the use of sex selection in conjunction
with the clinical use of MRTs. This recommendation has
the advantage of reducing the likelihood that future gen-
erations will suffer mitochondrial-related health compli-
cations and it also saves MRT-conceived female offspring
the future reproductive concern of potentially passing on
inheritable diseases to their own offspring (Bredenoord
et al. 2010: p. 1354).
This paper responds to the need for further ethical dis-
cussion about how regulators should improve the safety
and minimise the risk of making MRTs clinically acces-
sible for human use for the first time. Importantly, this
paper also calls for further discussion on both the ethical
issues it raises and the recommendations it offers. The
process of developing a robust framework for licensing the
clinical use of MRTs will be challenging and contentious,
and this process should be afforded ongoing scientific and
ethical scrutiny.
The recommendations made in this paper are discussed
in the context of UK regulations for MRTs and in relation
to how the techniques should be licensed by the HFEA for
use in UK clinics; however, these recommendations are
also relevant to international contexts (e.g. US or Sweden).
As MRTs and new novel ARTs like them are increasingly
developed and made clinically available, it is important
that countries, such as the UK, demonstrate the willingness
and capacity for detailed ethical review while these
28 Unfortunately, no follow-up research was conducted on children
conceived with CT and as a consequence there is no published data
available on the development and well being of this cohort.
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techniques make their way from bench to beside. The
perceived success of the HFEA’s ethical and scientific
review of MRTs (i.e. licensed clinical use) may impact
broader societal attitudes towards the moral permissibility
of introducing future ARTs. The ethical debates and rec-
ommendations discussed in this paper are an important part
of setting a precedent of rigorous discussion which will
inevitably inform expectations for debate surrounding the
introduction of future technologies.29
As researchers approach the first use of MRTs on
humans, more work remains to be done in order to ensure
that the licensing framework in place for clinics is ethical
by virtue of it minimising risks whenever possible. Taking
seriously the arguments and recommendations put forward
in this paper is an important step towards meeting this
ethical challenge.
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